Valeritas (NSDQ:VLRX) said today that it inked an expanded deal with Med Trust, its distribution partner in Austria and Germany, to promote and sell the V-Go wearable insulin delivery device in the Czech Republic and Slovakia.
According to the terms of the deal, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing the device while Med Trust will take over the sales, marketing and distribution activities.
“We are excited that our partner, Med Trust, has decided to expand its original distribution agreement to also include the Czech Republic and Slovakia,” CEO John Timberlake said in prepared remarks. “Having a well-respected partner like Med Trust decide to include two more countries in its distribution agreement not only gives us confidence in our decision to partner with Med Trust, it will provide patients with Type 2 diabetes in two more countries the ability to better manage their condition with V-Go.”
Earlier this year, Valeritas touted positive results from its Enable study, showing that patients who switched from insulin pens and syringes to the V-Go device experienced improved blood glucose levels and lowered their daily insulin dose.
